1tbr Citations

Two heads are better than one: crystal structure of the insect derived double domain Kazal inhibitor rhodniin in complex with thrombin.

Abstract

Rhodniin is a highly specific inhibitor of thrombin isolated from the assassin bug Rhodnius prolixus. The 2.6 Angstrum crystal structure of the non-covalent complex between recombinant rhodniin and bovine alpha-thrombin reveals that the two Kazal-type domains of rhodniin bind to different sites of thrombin. The amino-terminal domain binds in a substrate-like manner to the narrow active-site cleft of thrombin; the imidazole group of the P1 His residue extends into the S1 pocket to form favourable hydrogen/ionic bonds with Asp189 at its bottom, and additionally with Glu192 at its entrance. The carboxy-terminal domain, whose distorted reactive-site loop cannot adopt the canonical conformation, docks to the fibrinogen recognition exosite via extensive electrostatic interactions. The rather acidic polypeptide linking the two domains is displaced from the thrombin surface, with none of its residues involved in direct salt bridges with thrombin. The tight (Ki = 2 x 10(-13) M) binding of rhodniin to thrombin is the result of the sum of steric and charge complementarity of the amino-terminal domain towards the active-site cleft, and of the electrostatic interactions between the carboxy-terminal domain and the exosite.

Reviews - 1tbr mentioned but not cited (1)

  1. Exosite Binding in Thrombin: A Global Structural/Dynamic Overview of Complexes with Aptamers and Other Ligands. Troisi R, Balasco N, Autiero I, Vitagliano L, Sica F. Int J Mol Sci 22 10803 (2021)

Articles - 1tbr mentioned but not cited (1)



Reviews citing this publication (15)

  1. Nitrophorins and related antihemostatic lipocalins from Rhodnius prolixus and other blood-sucking arthropods. Montfort WR, Weichsel A, Andersen JF. Biochim Biophys Acta 1482 110-118 (2000)
  2. New anticoagulant drugs. Weitz JI, Hirsh J. Chest 119 95S-107S (2001)
  3. Structure and function of invertebrate Kazal-type serine proteinase inhibitors. Rimphanitchayakit V, Tassanakajon A. Dev Comp Immunol 34 377-386 (2010)
  4. Structural and energetic determinants of the S1-site specificity in serine proteases. Czapinska H, Otlewski J. Eur J Biochem 260 571-595 (1999)
  5. Cysteines and Disulfide Bonds as Structure-Forming Units: Insights From Different Domains of Life and the Potential for Characterization by NMR. Wiedemann C, Kumar A, Lang A, Ohlenschläger O. Front Chem 8 280 (2020)
  6. Rate constants and mechanisms of intrinsically disordered proteins binding to structured targets. Zhou HX, Pang X, Lu C. Phys Chem Chem Phys 14 10466-10476 (2012)
  7. Structure and interaction modes of thrombin. Bode W. Blood Cells Mol Dis 36 122-130 (2006)
  8. Targeting thrombin--rational drug design from natural mechanisms. Huntington JA, Baglin TP. Trends Pharmacol Sci 24 589-595 (2003)
  9. Natural inhibitors of thrombin. Huntington JA. Thromb Haemost 111 583-589 (2014)
  10. Thrombin inhibitors from different animals. Tanaka-Azevedo AM, Morais-Zani K, Torquato RJ, Tanaka AS. J Biomed Biotechnol 2010 641025 (2010)
  11. Endoproteinase-protein inhibitor interactions. Bode W, Fernandez-Catalan C, Nagase H, Maskos K. APMIS 107 3-10 (1999)
  12. The structure of thrombin, a chameleon-like proteinase. Bode W. J Thromb Haemost 3 2379-2388 (2005)
  13. Nitrophorins and nitrobindins: structure and function. De Simone G, Ascenzi P, di Masi A, Polticelli F. Biomol Concepts 8 105-118 (2017)
  14. Direct thrombin inhibitors: patents 2002-2012 (Review). Kong Y, Chen H, Wang YQ, Meng L, Wei JF. Mol Med Rep 9 1506-1514 (2014)
  15. Inhibition mechanisms of hematophagous invertebrate compounds acting on the host blood coagulation and platelet aggregation pathways. Urata J, Shojo H, Kaneko Y. Biochimie 85 493-500 (2003)

Articles citing this publication (80)



Related citations provided by authors (6)